THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

Q&A Dr. Jeffrey M. Drazen on drug trial results

September 12, 2004

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

  • E-mail|
  • Print|
  • Reprints|
  • |
Text size +

The editors of 11 top medical journals shook up the staid world of academic publishing this past week when they decided to stop printing results of drug trials that aren't registered in a central database. Globe biotechnology reporter Jeffrey Krasner spoke with Dr. Jeffrey M. Drazen , editor-in-chief of the New England Journal of Medicine, about how the policy should ... (Full Article: 670 Words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $4.95 1 Article
  • $9.95 4 Articles
  • $99.95 Unlimited